Cardinal Health Inc. Initiates Class II Recall of Genentech's Xolair (Omalizumab) Due to Cold Chain Failure
Cardinal Health Inc. has initiated a Class II recall for four units of Genentech's Xolair (omalizumab) due to temperature excursions, indicating CGMP deviations. This incident highlights persistent cold chain vulnerabilities within Cardinal Health's distribution network, following similar recalls for XIGDUO XR and RECOMBINATE. Procurement and supply chain leaders must reassess third-party logistics risks for temperature-sensitive biologics.
FDA Identifies CGMP Deviations in Cardinal Health's Xolair Distribution
On July 30, 2025, Cardinal Health Inc. initiated a Class II recall, D-0572-2025, for specific units of Genentech, Inc.'s Xolair (omalizumab injection), 75 mg/0.5 ml. The core issue, as identified by the FDA, stems from Current Good Manufacturing Practice (CGMP) deviations where the product was exposed to temperatures outside its labeled storage requirements. This directly impacts the stability and efficacy of omalizumab, a critical biologic. For procurement directors and regulatory affairs heads, this event underscores the absolute necessity of stringent temperature control throughout the pharmaceutical supply chain. Failure to maintain specified storage conditions for biologics like Xolair can compromise product quality, leading to potential patient safety risks and significant financial liabilities from product loss and recall management. The recall specifically targets Lot 3630004, with an expiration date of October 31, 2025, and NDC 50242-214-55. Although the recall involves a limited quantity of four units, its Class II classification indicates that exposure to the compromised product could lead to temporary or medically reversible adverse health consequences, or that the probability of serious adverse health consequences is remote. This mandates immediate action from all stakeholders in the distribution chain to identify and quarantine affected stock.
Product Impact and Market Implications for Xolair (Omalizumab)
The recalled product, Xolair (omalizumab injection), is a human prescription drug primarily administered subcutaneously. Manufactured by Genentech, Inc., this biologic is critical for treating conditions such as moderate to severe persistent asthma and chronic idiopathic urticaria. The specific product recalled is the 75 mg/0.5 ml presentation, identified by NDC 50242-214-55. While Genentech, Inc. is the manufacturer, Cardinal Health Inc. is the recalling firm, indicating the temperature excursion occurred within the distribution phase. The distribution pattern for the affected lot was nationwide within the U.S., meaning any facility or healthcare provider across the country that received this specific lot could be impacted. For business development executives and supply chain VPs, this incident highlights the vulnerability of even well-established product supply chains to distribution-level failures. The integrity of high-value biologics like omalizumab is paramount, and any deviation from storage requirements can erode trust and necessitate costly remediation efforts. Ensuring robust cold chain management from manufacturer to patient is not merely a regulatory requirement but a fundamental business imperative to protect product quality and market reputation.
Cardinal Health's Distribution Network and Supply Chain Exposure
Cardinal Health Inc., a prominent player in global healthcare services and product distribution, initiated this voluntary recall from its Dublin, OH, operations. As a major distributor, Cardinal Health's role in the pharmaceutical supply chain is extensive, handling numerous temperature-sensitive products. This recall, stemming from temperature deviations, suggests potential systemic issues within their cold chain logistics. For procurement directors, this event necessitates a critical review of all contracts and service level agreements (SLAs) with Cardinal Health, particularly concerning temperature-controlled storage and transport. The distribution of just four affected units nationwide, while small in quantity, still triggers a significant regulatory response and operational burden. Supply chain VPs must assess their exposure to similar risks across other temperature-sensitive products distributed by Cardinal Health. This incident underscores the importance of continuous monitoring and auditing of third-party logistics (3PL) partners to ensure their compliance with stringent storage requirements for all pharmaceutical products, especially biologics that are highly susceptible to temperature fluctuations.
Cardinal Health's Recurring Compliance Challenges: A Pattern of Temperature Excursions
This recall of Xolair by Cardinal Health Inc. is not an isolated incident but rather indicative of a recurring pattern of compliance challenges related to temperature control within their distribution network. ChemLifeIntel's intelligence reveals two prior Class II recalls initiated by Cardinal Health Inc. for similar reasons. On June 2, 2021, the company faced an FDA Class II recall for XIGDUO XR, also due to storage temperature excursions. More recently, on August 13, 2025, Cardinal Health initiated another Class II recall for RECOMBINATE, explicitly citing repeated temperature excursions as the cause. This history suggests a persistent vulnerability in Cardinal Health's cold chain management systems, moving beyond isolated errors to potentially systemic deficiencies. For regulatory affairs heads and business development executives, this pattern signals an elevated risk when partnering with or relying on Cardinal Health for the distribution of temperature-sensitive pharmaceutical products. The cumulative effect of these incidents could lead to increased regulatory scrutiny from the FDA, potentially impacting Cardinal Health's operational flexibility and reputation. Companies must factor this recurring compliance history into their risk assessments and consider diversifying their distribution partners or implementing more rigorous oversight mechanisms.
Strategic Risk Mitigation for Pharmaceutical Supply Chains
The repeated temperature excursion incidents involving Cardinal Health Inc. necessitate a strategic re-evaluation of risk mitigation strategies for all companies relying on third-party logistics providers for pharmaceutical distribution. Procurement directors should initiate immediate audits of their 3PL partners' cold chain capabilities, focusing on real-time temperature monitoring, deviation handling protocols, and corrective and preventive action (CAPA) implementation. It is crucial to ensure that contractual agreements include robust clauses for temperature control, liability for product loss due to excursions, and clear communication channels for incident reporting. Supply chain VPs should explore technologies such as IoT-enabled sensors and blockchain for enhanced traceability and transparency across the cold chain, moving beyond reactive recalls to proactive prevention. Furthermore, diversifying distribution channels for critical temperature-sensitive products can reduce reliance on a single provider and mitigate the impact of localized failures. This proactive approach is vital not only for regulatory compliance but also for safeguarding product integrity, patient trust, and ultimately, market share in a highly competitive and regulated industry.